Jefferies Maintains Buy on Kinnate Biopharma, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Roger Song has maintained a 'Buy' rating on Kinnate Biopharma (NASDAQ:KNTE), but lowered the price target from $31 to $2.
September 19, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies has maintained a 'Buy' rating on Kinnate Biopharma but lowered the price target significantly from $31 to $2.
The significant reduction in price target from $31 to $2 by Jefferies, despite maintaining a 'Buy' rating, could negatively impact investor sentiment and potentially lead to a short-term decrease in Kinnate Biopharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100